LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Pfizer

Затворен

СекторЗдравеопазване

25.06 0.4

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.85

Максимум

25.16

Ключови измерители

By Trading Economics

Приходи

-45M

2.9B

Продажби

938M

15B

P/E

Средно за сектора

13.302

35.724

EPS

0.78

Дивидентна доходност

6.57

Марж на печалбата

19.982

Служители

81,000

EBITDA

266M

5.3B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+14.61% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

6.57%

3.09%

Следващи печалби

28.10.2025 г.

Следваща дата на дивидент

2.09.2025 г.

Следваща дата на екс-дивидент

7.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

9.2B

143B

Предишно отваряне

24.66

Предишно затваряне

25.06

Настроения в новините

By Acuity

35%

65%

105 / 372 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Pfizer Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2025 г., 11:34 ч. UTC

Печалби

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

5.08.2025 г., 20:44 ч. UTC

Печалби

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 18:20 ч. UTC

Печалби

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5.08.2025 г., 18:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 16:04 ч. UTC

Пазарно говорене

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5.08.2025 г., 15:25 ч. UTC

Печалби

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5.08.2025 г., 13:56 ч. UTC

Печалби

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5.08.2025 г., 11:43 ч. UTC

Печалби

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5.08.2025 г., 11:27 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:57 ч. UTC

Печалби

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5.08.2025 г., 10:55 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:53 ч. UTC

Печалби

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5.08.2025 г., 10:51 ч. UTC

Печалби

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

5.08.2025 г., 10:50 ч. UTC

Печалби

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

5.08.2025 г., 10:49 ч. UTC

Печалби

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

5.08.2025 г., 10:49 ч. UTC

Печалби

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

5.08.2025 г., 10:48 ч. UTC

Печалби

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

5.08.2025 г., 10:48 ч. UTC

Печалби

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

5.08.2025 г., 10:47 ч. UTC

Печалби

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

5.08.2025 г., 10:46 ч. UTC

Печалби

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

5.08.2025 г., 10:45 ч. UTC

Печалби

Pfizer Raises 2025 EPS Guidance >PFE

5.08.2025 г., 10:45 ч. UTC

Печалби

Pfizer 2Q EPS 51c >PFE

5.08.2025 г., 10:45 ч. UTC

Печалби

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

5.08.2025 г., 10:45 ч. UTC

Печалби

Pfizer 2Q Adj EPS 78c >PFE

5.08.2025 г., 10:45 ч. UTC

Печалби

Pfizer 2Q Rev $14.7B >PFE

5.08.2025 г., 10:45 ч. UTC

Печалби

Pfizer Sees FY Rev $61B-$64B >PFE

4.08.2025 г., 15:26 ч. UTC

Печалби

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

30.07.2025 г., 18:36 ч. UTC

Печалби

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

9.07.2025 г., 09:17 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

10.06.2025 г., 12:18 ч. UTC

Печалби

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Pfizer Прогноза

Ценова цел

By TipRanks

14.61% нагоре

12-месечна прогноза

Среден 28.56 USD  14.61%

Висок 33 USD

Нисък 24 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Pfizer през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

6

Купи

12

Задържане

0

Продай

Техническа оценка

By Trading Central

22.855 / 23.85Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

105 / 372 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.